Non-alcoholic fatty liver disease: A review with clinical and pathological correlation

被引：26
作者：
Chen, Yen-Ying [1 ,2 ]
Yeh, Matthew M. [3 ,4 ]
机构：
[1] Taipei Vet Gen Hosp, Dept Pathol & Lab Med, Taipei, Taiwan
[2] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan
[3] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA
[4] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA
来源：
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION | 2021年 / 120卷 / 01期
关键词：
Fatty liver; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; GLOBAL EPIDEMIOLOGY; STEATOHEPATITIS; PREVALENCE; FIBROSIS; NAFLD; METAANALYSIS; ASSOCIATION; DIAGNOSIS; STEATOSIS; ALGORITHM;
D O I：
10.1016/j.jfma.2020.07.006
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in North America and Europe, with increasing prevalence in other regions of the world. Its spectrum encompass steatosis, non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis. It is considered as the manifestation of metabolic syndrome in liver, and its development and progression is influenced by complex interaction of environmental and genetic factors. In this review we discuss the histopathological features, differential diagnoses, and the commonly used grading and staging systems of NAFLD. NAFLD associated with other diseases, histological changes after therapeutic intervention and recurrence or occurrence of NAFLD after liver transplantation are also addressed. Copyright (C) 2020, Formosan Medical Association. Published by Elsevier Taiwan LLC.
引用
收藏
页码：68 / 77
页数：10
相关论文
共 50 条
  • [31] Epidemiology of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A focused literature review
    Eguchi, Yuichiro
    Wong, Gabriel
    Lee, Emma
    Akhtar, Omar
    Lopes, Ricardo
    Sumida, Yoshio
    JGH OPEN, 2020, 4 (05): : 808 - 817
  • [32] Treatment of Non-Alcoholic Fatty Liver Disease
    Scherer, Antonia
    Dufour, Jean-Francois
    DIGESTIVE DISEASES, 2016, 34 : 27 - 31
  • [33] Non-alcoholic fatty liver disease and steatohepatitis
    Par Gabriella
    Horvath Gabor
    Par Alajos
    ORVOSI HETILAP, 2013, 154 (29) : 1124 - 1134
  • [34] Non-Alcoholic Fatty Liver Disease in Cuba
    Castellanos-Fernandez, Marlen, I
    Crespo-Ramirez, Eduardo
    del Valle-Diaz, Sergio
    Barreto-Suarez, Eduardo
    Diaz-Elias, Javier O.
    Santalo-Rodriguez, Lorenzo
    Corrales-Alonso, Sahili
    Morales-Martinez, Ignacio
    Cedeno-Ramirez, Elisa
    Perez-Gonzalez, Teresita
    Gonzalez-Suero, Sila M.
    Ruenes-Domech, Caridad
    Infante-Velazquez, Mirtha
    Borges-Gonzalez, Susana A.
    Elvirez-Gutierrez, Angela
    Lazo-del Vallin, Sacha
    Villa-Jimenez, Oscar M.
    Labrada-Moreno, Liana M.
    MEDICC REVIEW, 2021, 23 (01) : 64 - 71
  • [35] The Prevalence of Non-Alcoholic Fatty Liver Disease in Iranian Children and Adult Population: A Systematic Review and Meta-Analysis
    Hassanipour, Soheil
    Amini-Salehi, Ehsan
    Joukar, Farahnaz
    Khosousi, Mohammad-Javad
    Pourtaghi, Farideh
    Ansar, Malek Moein
    Mahdavi-Roshan, Marjan
    Heidarzad, Forough
    Rashidi-Mojdehi, Golnaz
    Abdzadeh, Elham
    Vakilpour, Azin
    Mansour-Ghanaei, Fariborz
    IRANIAN JOURNAL OF PUBLIC HEALTH, 2023, 52 (08) : 1600 - 1612
  • [36] Coffee Consumption and Non-alcoholic Fatty Liver Disease: An Umbrella Review and a Systematic Review and Meta-analysis
    Kositamongkol, Chayanis
    Kanchanasurakit, Sukrit
    Auttamalang, Chiraphong
    Inchai, Nutkamon
    Kabkaew, Thanatchaporn
    Kitpark, Sarunporn
    Chaiyakunapruk, Nathorn
    Duangjai, Acharaporn
    Saokaew, Surasak
    Phisalprapa, Pochamana
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [37] Non-alcoholic fatty liver disease proteomics
    Rodriguez-Suarez, Eva
    Duce, Antonio M.
    Caballeria, Juan
    Martinez Arrieta, Felix
    Fernandez, Estefania
    Gomara, Carolina
    Alkorta, Nere
    Ariz, Usue
    Luz Martinez-Chantar, M.
    Lu, Shelly C.
    Elortza, Felix
    Mato, Jose M.
    PROTEOMICS CLINICAL APPLICATIONS, 2010, 4 (04) : 362 - 371
  • [38] An Update on the Effect Of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease: A Systematic Review of Clinical Trials
    Alfayez, Abdulrahman I.
    Alfallaj, Jawaher M.
    Mobark, Mugahid A.
    Alalwan, Abdullah A.
    Alfayez, Osamah M.
    CURRENT DIABETES REVIEWS, 2024, 20 (02) : 131 - 144
  • [39] Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease
    Miyake, Teruki
    Yoshida, Sakiko
    Furukawa, Shinya
    Sakai, Takenori
    Tada, Fujimasa
    Senba, Hidenori
    Yamamoto, Shin
    Koizumi, Yohei
    Yoshida, Osamu
    Hirooka, Masashi
    Kumagi, Teru
    Niiya, Tetsuju
    Miyaoka, Hiroaki
    Masanori, Abe
    Matsuura, Bunzo
    Hiasa, Yoichi
    OPEN MEDICINE, 2018, 13 (01): : 402 - 409
  • [40] Managing non-alcoholic fatty liver disease
    Ngu, Jing Hieng
    Goh, George Boon Bee
    Poh, Zhongxian
    Soetikno, Roy
    SINGAPORE MEDICAL JOURNAL, 2016, 57 (07) : 368 - 370
12345